Literature DB >> 28958694

Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: Clinical, genetic and atherosclerotic burden profile.

R Scicali1, A Di Pino1, R Platania1, G Purrazzo1, V Ferrara1, A Giannone1, F Urbano1, A Filippello1, V Rapisarda2, E Farruggia3, S Piro1, A M Rabuazzo1, F Purrello4.   

Abstract

BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is underdiagnosed and public cholesterol screening may be useful to find new subjects. In this study, we aim to investigate the prevalence of FH patients in a hospital screening program and evaluate their atherosclerotic burden using intima-media thickness (IMT). METHODS AND
RESULTS: We screened 1575 lipid profiles and included for genetic analysis adults with a low-density lipoprotein (LDL) cholesterol >190 mg/dL and triglycerides <200 mg/dL and first-degree child relatives with LDL cholesterol >160 mg/dL and triglycerides <200 mg/dL. The diagnosis of FH was presumed by Dutch Lipid Clinic Network (DLCN) criteria and confirmed by the presence of the genetic variant. Mean common carotid intima-media thickness (IMT) was assessed using consensus criteria. After confirming LDL cholesterol value and excluding secondary hypercholesterolemia, 56 subjects with a DLCN ≥4 performed genetic analysis. Of these, 26 had an FH genetic variant. The proportion of patients with a mutation having a DLCN score of 6-8 was 75%; in individuals with a DLCN score >8 it was 100%. Mean IMT was higher in FH patients compared to non FH (0.73 [0.61-0.83] vs 0.71 [0.60-0.75] mm, p < 0.01). Moreover, we detected two mutations not previously described. Finally, simple regression analysis showed a correlation of IMT with LDL cholesterol >190 mg/dL and corneal arcus (p < 0.01 and p < 0.001, respectively).
CONCLUSIONS: A hospital screening was useful to detect FH subjects with increased atherosclerosis. Also, next-generation sequencing was able to detect new FH mutations.
Copyright © 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk assessment; Familial hypercholesterolemia; Intima-media thickness; Low-density lipoprotein cholesterol; Screening program

Mesh:

Substances:

Year:  2017        PMID: 28958694     DOI: 10.1016/j.numecd.2017.07.003

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  4 in total

1.  Implementation of a biochemical, clinical, and genetic screening programme for familial hypercholesterolemia in 26 centres in Spain: The ARIAN study.

Authors:  Teresa Arrobas Velilla; Ángel Brea; Pedro Valdivielso
Journal:  Front Genet       Date:  2022-08-29       Impact factor: 4.772

2.  Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation.

Authors:  Roberto Scicali; Antonino Di Pino; Chiara Pavanello; Alice Ossoli; Arianna Strazzella; Antonia Alberti; Stefania Di Mauro; Alessandra Scamporrino; Francesca Urbano; Agnese Filippello; Salvatore Piro; Agata Maria Rabuazzo; Laura Calabresi; Francesco Purrello
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

3.  Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience.

Authors:  Roberto Scicali; Giorgio Ivan Russo; Marina Di Mauro; Flavia Manuele; Grazia Di Marco; Antonino Di Pino; Viviana Ferrara; Agata Maria Rabuazzo; Salvatore Piro; Giuseppe Morgia; Francesco Purrello
Journal:  J Clin Med       Date:  2020-11-08       Impact factor: 4.241

Review 4.  Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents.

Authors:  Hayato Tada; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  Vasc Health Risk Manag       Date:  2021-02-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.